hyperphosphatemia

6-Acryloyloxyhexyl phosphater (PA21) is a novel phosphate-binding agent, which is an iron-based reagent, and can be used for the treatment of hyperphosphatemia in chronic kidney disease.

Sevelamer hydrochloride (Sevelamer HCl) is a phosphate binding drug used to treat hyperphosphatemia via binding to dietary phosphate and prevents its absorption.

Tenapanor (RDX 5791) is an inhibitor of the sodium-proton (Na(+) H(+)) exchanger NHE3, which plays a prominent role in sodium handling in the gastrointestinal tract and kidney. Tenapanor possesses an excellent preclinical safety profile and, as of now, there are no serious concerns about its side effects.

NaPi2b is primarily expressed in the small intestine, lungs, and testes and plays an important role in phosphate homeostasis. The inhibition of NaPi2b, responsible for intestinal phosphate absorption, is considered to reduce serum phosphate levels, making it a promising therapeutic approach for hyperphosphatemia

NaPi2b-IN-2 (compound 5) is a potent inhibitor of the sodium-dependent transport protein 2b (SLC34A2, NaPi2b), with an IC50 of 38 nM against human NaPi2b. It holds potential for hyperphosphatemia research [1].

Canvuparatide (MBX 2109) is a prodrug of a parathyroid hormone (PTH) peptide that releases a bioactive PTH[1-32] agonist peptide. This peptide retains a C-terminal fatty acylated lysine (Lys33), which extends the half-life of Canvuparatide. It is utilized in the study of hypoparathyroidism symptoms such as hypocalcemia and hyperphosphatemia.